GLRA3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4187068	0.63	9/20
SCHEMBL4180216	0.55	7/20
SCHEMBL1975364	0.49	4/20
SCHEMBL4391138	0.45	3/20
SCHEMBL3523178	0.41	3/20
SCHEMBL2594171	0.36	3/20
SCHEMBL4750473	0.33	3/20
SCHEMBL4424508	0.64	2/20
SCHEMBL4372456	0.60	2/20
SCHEMBL1115678	0.59	2/20
SCHEMBL250575	0.58	2/20
SCHEMBL1115580	0.58	2/20
Hydrochloric Acid (SCHEMBL5838632)	0.58	2/20
SCHEMBL3453971	0.56	2/20
SCHEMBL1583365	0.51	2/20
Hydrochloric Acid (SCHEMBL1582253)	0.50	2/20
Hydrochloric Acid (SCHEMBL1582269)	0.50	2/20
SCHEMBL249779	0.48	2/20
SCHEMBL3105351	0.47	2/20
SCHEMBL3263766	0.46	2/20

Clinical trials — most relevant to GLRA3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effects of Levetiracetam on Alcohol Dependent Subjects	PHASE4	COMPLETED
Pilot Study: Postoperative Pain Reduction by Pre Emptive N-Acetylcysteine	PHASE4	COMPLETED
Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers	PHASE3	COMPLETED
Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors	PHASE2/PHASE3	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure	PHASE2	UNKNOWN
Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia	PHASE2	COMPLETED
Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia	PHASE2	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia	PHASE2	WITHDRAWN
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203	PHASE1	COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
Open-Trial of EPI-743 for Adults With Tourette Syndrome	PHASE1	COMPLETED
Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer	PHASE1	WITHDRAWN
Excitatory Amino Acids and Activated Microglia After Traumatic Brain Injury: a (R)-[11C]PK11195 PET Study	PHASE1	UNKNOWN
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Changes in Glutamatergic Neurotransmission of Severe TBI Patients	EARLY_PHASE1	SUSPENDED
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms	nan	COMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
Metabotropic Receptors For Glutamate Type 3 In Parkinson's	nan	UNKNOWN
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
A Positional Cloning Study on Schizophrenia	nan	COMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy	nan	UNKNOWN
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Y-3 Injection Through Skull Bone Marrow in the Treatment of Acute Malignant Middle Cerebral Artery Infarction (SOLUTION)	nan	COMPLETED
The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a GLRA3 binder may also engage these)

Protein	Name	Similarity
Q91XP5	—	1.000	Q91XP5 →
GLRA1	Glycine receptor subunit alpha-1	1.000	landscape →
P24524	—	1.000	P24524 →
GLRA2	Glycine receptor subunit alpha-2	1.000	landscape →
Q64018	—	1.000	Q64018 →
P22771	—	1.000	P22771 →
F1R8P4	—	1.000	F1R8P4 →
Q61603	—	0.998	Q61603 →
O93430	—	0.997	O93430 →
P57695	—	0.997	P57695 →
P07727	—	0.996	P07727 →
Q7TNC8	—	0.996	Q7TNC8 →
Q17328	—	0.994	Q17328 →
Q94900	—	0.991	Q94900 →
P26714	—	0.989	P26714 →
G5EBR3	—	0.989	G5EBR3 →
P22933	—	0.989	P22933 →
P18506	—	0.988	P18506 →
P91730	—	0.986	P91730 →
GABRD	Gamma-aminobutyric acid receptor subunit delta	0.985	landscape →
O18276	—	0.978	O18276 →
P02712	—	0.978	P02712 →
P26153	—	0.977	P26153 →
P48168	—	0.977	P48168 →
A8WQK3	—	0.977	A8WQK3 →
GLRB	Glycine receptor subunit beta (Glycine recept	0.977	landscape →
Q5EA06	—	0.977	Q5EA06 →
P05376	—	0.976	P05376 →
Q08832	—	0.976	Q08832 →
P20781	—	0.976	P20781 →